Sapho Bio

Sapho Bio is a clinical-stage biopharmaceutical company headquartered in Shanghai, China, dedicated to the discovery and development of next-generation small molecule therapeutics for autoimmune and inflammatory diseases. The company utilizes a proprietary drug discovery platform focused on high-selectivity kinase inhibitors to address significant unmet medical needs in dermatology and rheumatology. Its lead program, SP-101, is a highly selective Tyrosine kinase 2 (TYK2) inhibitor currently undergoing Phase 2 clinical evaluation for the treatment of plaque psoriasis. Beyond TYK2, Sapho Bio is advancing a pipeline of selective Janus kinase 1 (JAK1) inhibitors and other novel candidates targeting oncology and chronic inflammation. The company is backed by prominent life science investors, including Qiming Venture Partners and TF Capital. Sapho Bio aims to deliver best-in-class treatments that offer improved safety profiles compared to existing systemic therapies.